Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

The role of heterogeneous environment and docetaxel gradient in the emergence of polyploid, mesenchymal and resistant prostate cancer cells.

Lin KC, Torga G, Sun Y, Axelrod R, Pienta KJ, Sturm JC, Austin RH.

Clin Exp Metastasis. 2019 Apr;36(2):97-108. doi: 10.1007/s10585-019-09958-1. Epub 2019 Feb 27.

PMID:
30810874
2.

Nanostructural Properties and Twist Periodicity of Cellulose Nanofibrils with Variable Charge Density.

Arcari M, Zuccarella E, Axelrod R, Adamcik J, Sánchez-Ferrer A, Mezzenga R, Nyström G.

Biomacromolecules. 2019 Mar 11;20(3):1288-1296. doi: 10.1021/acs.biomac.8b01706. Epub 2019 Feb 6.

PMID:
30673281
3.

Socioeconomic inequalities in exposure to environmental tobacco smoke in children in Israel.

Berman T, Barnett-Itzhaki Z, Axelrod R, Keinan-Boker L, Shimony T, Goldsmith R, Göen T, Geva H, Rosen L.

Environ Int. 2018 Dec;121(Pt 1):643-648. doi: 10.1016/j.envint.2018.09.034. Epub 2018 Oct 10.

4.

Cancer as a Social Dysfunction-Why Cancer Research Needs New Thinking.

Axelrod R, Pienta KJ.

Mol Cancer Res. 2018 Sep;16(9):1346-1347. doi: 10.1158/1541-7786.MCR-18-0013. Epub 2018 May 21.

PMID:
29784670
5.

Not All Head and Neck Squamous Cell Carcinomas Are Created Equal: Some Are More Aggressive.

Man LC, Axelrod R.

Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1063. doi: 10.1016/j.ijrobp.2017.07.006. No abstract available.

PMID:
29165276
6.

Evaluation of critical congenital heart defects screening using pulse oximetry in the neonatal intensive care unit.

Van Naarden Braun K, Grazel R, Koppel R, Lakshminrusimha S, Lohr J, Kumar P, Govindaswami B, Giuliano M, Cohen M, Spillane N, Jegatheesan P, McClure D, Hassinger D, Fofah O, Chandra S, Allen D, Axelrod R, Blau J, Hudome S, Assing E, Garg LF.

J Perinatol. 2017 Oct;37(10):1117-1123. doi: 10.1038/jp.2017.105. Epub 2017 Jul 27.

7.

Tunable resonance-domain diffraction gratings based on electrostrictive polymers.

Axelrod R, Shacham-Diamand Y, Golub MA.

Appl Opt. 2017 Mar 1;56(7):1817-1825. doi: 10.1364/AO.56.001817.

PMID:
28248376
8.

Strategic aspects of cyberattack, attribution, and blame.

Edwards B, Furnas A, Forrest S, Axelrod R.

Proc Natl Acad Sci U S A. 2017 Mar 14;114(11):2825-2830. doi: 10.1073/pnas.1700442114. Epub 2017 Feb 27.

9.

Challenges in researching terrorism from the field.

Atran S, Axelrod R, Davis R, Fischhoff B.

Science. 2017 Jan 27;355(6323):352-354. doi: 10.1126/science.aaj2037. No abstract available.

PMID:
28126773
10.

The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Weidhaas JB, Harris J, Schaue D, Chen AM, Chin R, Axelrod R, El-Naggar AK, Singh AK, Galloway TJ, Raben D, Wang D, Matthiesen C, Avizonis VN, Manon RR, Yumen O, Nguyen-Tan PF, Trotti A, Skinner H, Zhang Q, Ferris RL, Sidransky D, Chung CH.

JAMA Oncol. 2017 Apr 1;3(4):483-491. doi: 10.1001/jamaoncol.2016.5478.

11.

Neutrophil to lymphocyte ratio associated with prognosis of lung cancer.

Bar-Ad V, Palmer J, Li L, Lai Y, Lu B, Myers RE, Ye Z, Axelrod R, Johnson JM, Werner-Wasik M, Cowan SW, Evans NR, Hehn BT, Solomides CC, Wang C.

Clin Transl Oncol. 2017 Jun;19(6):711-717. doi: 10.1007/s12094-016-1593-y. Epub 2016 Dec 1.

PMID:
27909873
12.

The Paradox of Abstraction: Precision Versus Concreteness.

Iliev R, Axelrod R.

J Psycholinguist Res. 2017 Jun;46(3):715-729. doi: 10.1007/s10936-016-9459-6.

PMID:
27878506
13.

Linguistic positivity in historical texts reflects dynamic environmental and psychological factors.

Iliev R, Hoover J, Dehghani M, Axelrod R.

Proc Natl Acad Sci U S A. 2016 Dec 6;113(49):E7871-E7879. Epub 2016 Nov 21. Erratum in: Proc Natl Acad Sci U S A. 2017 Jan 3;:.

14.

Shift-bonded resonance-domain diffraction gratings.

Axelrod R, Shacham-Diamand Y, Golub M.

Appl Opt. 2016 Oct 20;55(30):8606-8611. doi: 10.1364/AO.55.008606.

PMID:
27828143
15.

Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522.

Truong MT, Zhang Q, Rosenthal DI, List M, Axelrod R, Sherman E, Weber R, Nguyen-Tân PF, El-Naggar A, Konski A, Galvin J, Schwartz D, Trotti A, Silverman C, Singh A, Godette K, Bonner JA, Jones CU, Garden AS, Shenouda G, Matthiesen C, Le QT, Bruner D.

Int J Radiat Oncol Biol Phys. 2017 Mar 15;97(4):687-699. doi: 10.1016/j.ijrobp.2016.08.003. Epub 2016 Aug 12.

16.

PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.

Wirth LJ, Dakhil S, Kornek G, Axelrod R, Adkins D, Pant S, O'Brien P, Debruyne PR, Oliner KS, Dong J, Murugappan S.

Oral Oncol. 2016 Oct;61:31-40. doi: 10.1016/j.oraloncology.2016.07.005. Epub 2016 Aug 20.

PMID:
27688102
17.

Phase I Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib With Concurrent Radiotherapy for Advanced Head and Neck Cancer.

Ahn PH, Machtay M, Anne PR, Cognetti D, Keane WM, Wuthrick E, Dicker AP, Axelrod RS.

Am J Clin Oncol. 2018 May;41(5):441-446. doi: 10.1097/COC.0000000000000317.

PMID:
27391356
18.

Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience.

Bar-Ad V, Zhang QE, Harari PM, Axelrod R, Rosenthal DI, Trotti A, Jones CU, Garden AS, Song G, Foote RL, Raben D, Shenouda G, Spencer SA, Harris J, Le QT.

Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1346-1354. doi: 10.1016/j.ijrobp.2016.03.011. Epub 2016 Mar 26.

19.

Does Causality Matter More Now? Increase in the Proportion of Causal Language in English Texts.

Iliev R, Axelrod R.

Psychol Sci. 2016 May;27(5):635-43. doi: 10.1177/0956797616630540. Epub 2016 Mar 18.

PMID:
26993741
20.

Reply to D. Adkins et al.

Axelrod RS, Sherman E, Garden A, Nguyen-Tan PF, Trotti A, Yom SS, Zhang Q.

J Clin Oncol. 2015 Apr 1;33(10):1224-5. doi: 10.1200/JCO.2014.59.9431. Epub 2015 Feb 23. No abstract available.

PMID:
25713438
21.

Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer.

Ramalingam SS, Shtivelband M, Soo RA, Barrios CH, Makhson A, Segalla JG, Pittman KB, Kolman P, Pereira JR, Srkalovic G, Belani CP, Axelrod R, Owonikoko TK, Qin Q, Qian J, McKeegan EM, Devanarayan V, McKee MD, Ricker JL, Carlson DM, Gorbunova VA.

J Clin Oncol. 2015 Feb 10;33(5):433-41. doi: 10.1200/JCO.2014.55.7173. Epub 2015 Jan 5.

22.

Current management of locally advanced head and neck cancer: the combination of chemotherapy with locoregional treatments.

Bar-Ad V, Palmer J, Yang H, Cognetti D, Curry J, Luginbuhl A, Tuluc M, Campling B, Axelrod R.

Semin Oncol. 2014 Dec;41(6):798-806. doi: 10.1053/j.seminoncol.2014.09.018. Epub 2014 Oct 7. Review.

PMID:
25499638
23.

Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.

Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar AK, Gillison ML, Jordan RC, Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS, Axelrod RS.

J Clin Oncol. 2014 Sep 20;32(27):2940-50.

24.

A pilot study of hypofractionated stereotactic radiation therapy and sunitinib in previously irradiated patients with recurrent high-grade glioma.

Wuthrick EJ, Curran WJ Jr, Camphausen K, Lin A, Glass J, Evans J, Andrews DW, Axelrod R, Shi W, Werner-Wasik M, Haacke EM, Hillman GG, Dicker AP.

Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):369-75. doi: 10.1016/j.ijrobp.2014.05.034. Epub 2014 Aug 4.

PMID:
25104067
25.

Modeling the overall survival of patients with advanced-stage non-small cell lung cancer using data of routine laboratory tests.

Zhang K, Lai Y, Axelrod R, Campling B, Hyslop T, Civan J, Solomides C, Myers RE, Lu B, Bar Ad V, Li B, Ye Z, Yang H.

Int J Cancer. 2015 Jan 15;136(2):382-91. doi: 10.1002/ijc.28995. Epub 2014 Jun 5.

26.

Timing of cyber conflict.

Axelrod R, Iliev R.

Proc Natl Acad Sci U S A. 2014 Jan 28;111(4):1298-303. doi: 10.1073/pnas.1322638111. Epub 2014 Jan 13.

27.

E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer.

Owonikoko TK, Aisner J, Wang XV, Dahlberg SE, Rubin EH, Ramalingam SS, Gounder M, Rausch PG, Axelrod RS, Schiller JH.

Cancer Chemother Pharmacol. 2014 Jan;73(1):171-80. doi: 10.1007/s00280-013-2338-z. Epub 2013 Nov 28.

28.

Sarcoidosis mimicking metastatic bone disease in head and neck cancer.

Arana Yi C, McCue P, Rosen M, Machtay M, Axelrod R, Morris GJ.

Semin Oncol. 2013 Oct;40(5):529-34. doi: 10.1053/j.seminoncol.2013.05.015. No abstract available.

PMID:
24135396
29.

Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab.

Zaorsky NG, Sun Y, Wang Z, Palmer J, Fortina PM, Solomides C, Werner-Wasik M, Dicker AP, Axelrod R, Campling B, Evans N 3rd, Cowan S, Lu B.

Cancer Biol Ther. 2013 Oct 1;14(10):883-7. doi: 10.4161/cbt.25942. Epub 2013 Aug 2.

30.

The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801.

Lawrence YR, Paulus R, Langer C, Werner-Wasik M, Buyyounouski MK, Komaki R, Machtay M, Smith C, Axelrod RS, Wasserman T, Bradley JD, Movsas B.

Lung Cancer. 2013 Jun;80(3):298-305. doi: 10.1016/j.lungcan.2013.02.008. Epub 2013 Mar 7.

31.

An economic model to value companion diagnostics in non-small-cell lung cancer.

Lieberthal RD, Dudash K, Axelrod R, Goldfarb NI.

Per Med. 2013 Mar;10(2):139-147. doi: 10.2217/pme.13.7.

PMID:
29758848
32.

Treatment-related acute esophagitis for patients with locoregionally advanced non-small cell lung cancer treated with involved-field radiotherapy and concurrent chemotherapy.

Bar-Ad V, Leiby B, Witek M, Xiao Y, Cui Y, Dai Y, Cao J, Axelrod R, Campling B, Both S, Werner-Wasik M.

Am J Clin Oncol. 2014 Oct;37(5):433-7. doi: 10.1097/COC.0b013e31827de7a2.

PMID:
23388558
33.

Value of fluoro-2-deoxy-D-glucose-positron emission tomography for detecting metastatic lesions in head and neck cancer.

Fogh SE, Kubicek GJ, Champ C, Intenzo C, Axelrod R, Keane WM, Machtay MM.

Am J Clin Oncol. 2012 Aug;35(4):311-5. doi: 10.1097/COC.0b013e3181ec5f2e.

PMID:
22772424
34.

Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies.

Kubicek GJ, Axelrod RS, Machtay M, Ahn PH, Anne PR, Fogh S, Cognetti D, Myers TJ, Curran WJ Jr, Dicker AP.

Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1192-7. doi: 10.1016/j.ijrobp.2011.09.023. Epub 2012 Jan 13.

PMID:
22245208
35.

Endovascular management of carotid blowout.

Zussman B, Gonzalez LF, Dumont A, Tjoumakaris S, Rosenwasser R, Hasan D, Cognetti D, Axelrod R, Jabbour P.

World Neurosurg. 2012 Jul;78(1-2):109-14. doi: 10.1016/j.wneu.2011.08.024. Epub 2011 Nov 7.

PMID:
22120297
36.

A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies.

Wuthrick EJ, Kamrava M, Curran WJ Jr, Werner-Wasik M, Camphausen KA, Hyslop T, Axelrod R, Andrews DW, Glass J, Machtay M, Dicker AP.

Cancer. 2011 Dec 15;117(24):5548-59. doi: 10.1002/cncr.26216. Epub 2011 Jun 3.

37.

Launching "the evolution of cooperation".

Axelrod R.

J Theor Biol. 2012 Apr 21;299:21-4. doi: 10.1016/j.jtbi.2011.04.015. Epub 2011 Apr 22.

PMID:
21540040
38.

Phase i study of 'dose-dense' pemetrexed plus carboplatin/radiotherapy for locally advanced non-small cell lung carcinoma.

Shen X, Denittis A, Werner-Wasik M, Axelrod R, Gilman P, Meyer T, Treat J, Curran WJ, Machtay M.

Radiat Oncol. 2011 Feb 16;6:17. doi: 10.1186/1748-717X-6-17.

39.
40.

Human papillomavirus and survival of patients with oropharyngeal cancer.

Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML.

N Engl J Med. 2010 Jul 1;363(1):24-35. doi: 10.1056/NEJMoa0912217. Epub 2010 Jun 7.

41.

Introduction: women and lung cancer.

Axelrod RS.

Semin Oncol. 2009 Dec;36(6):504-5. doi: 10.1053/j.seminoncol.2009.10.006. No abstract available.

PMID:
19995641
42.

Phase I trial using patupilone (epothilone B) and concurrent radiotherapy for central nervous system malignancies.

Fogh S, Machtay M, Werner-Wasik M, Curran WJ Jr, Bonanni R, Axelrod R, Andrews D, Dicker AP.

Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1009-16. doi: 10.1016/j.ijrobp.2009.06.050. Epub 2009 Oct 30.

PMID:
19879067
43.

Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group.

Argiris A, Buchanan A, Brockstein B, Kolesar J, Ghebremichael M, Pins M, Hahn K, Axelrod R, Forastiere A.

Cancer. 2009 Oct 1;115(19):4504-13. doi: 10.1002/cncr.24528.

44.
45.

A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study.

Burtness BA, Manola J, Axelrod R, Argiris A, Forastiere AA; Eastern Cooperative Oncology Group.

Ann Oncol. 2008 May;19(5):977-83. doi: 10.1093/annonc/mdm591. Epub 2008 Feb 21.

PMID:
18296423
46.

Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.

Lilenbaum R, Axelrod R, Thomas S, Dowlati A, Seigel L, Albert D, Witt K, Botkin D.

J Clin Oncol. 2008 Feb 20;26(6):863-9. doi: 10.1200/JCO.2007.13.2720.

PMID:
18281658
47.

Neck dissection followed by chemoradiotherapy for stage IV (N+) oropharynx cancer.

Cupino A, Axelrod R, Anne PR, Sidhu K, Lavarino J, Kung B, Rosen M, Keane W, Machtay M.

Otolaryngol Head Neck Surg. 2007 Sep;137(3):416-21.

PMID:
17765768
48.

Social science. Sacred barriers to conflict resolution.

Atran S, Axelrod R, Davis R.

Science. 2007 Aug 24;317(5841):1039-40. No abstract available.

PMID:
17717171
49.

Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.

Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP, Govindan R, Raez LE, Robert F, Ribeiro M, Akerley W, Kelly K, Limentani SA, Crawford J, Reimers HJ, Axelrod R, Kashala O, Sheng S, Schiller JH.

J Clin Oncol. 2006 Nov 1;24(31):5025-33.

PMID:
17075122
50.

Evolution of cooperation among tumor cells.

Axelrod R, Axelrod DE, Pienta KJ.

Proc Natl Acad Sci U S A. 2006 Sep 5;103(36):13474-9. Epub 2006 Aug 28. Review.

Supplemental Content

Loading ...
Support Center